More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

What may be in store for the pharma industry in 2021? What trends will continue and what will emerge? From telemedicine to new models in drug development, to supply-chain adjustments, to increased deal-making, DCAT Value Chain Insights takes the...

The European Commission’s Pharmaceutical Strategy for Europe calls for a structured dialogue to identify vulnerabilities in the pharma supply chain and provide policy options to strengthen medicines supply in the EU, including reducing EU...

In 2020, the FDA approved 53 new molecular entities (NMEs), the second highest level of NMEs approved in a given year in the past decade and over the 48 approvals in 2019. What drugs were approved, and what was the mix between small molecules and...

COVID-19 will continue to be a defining issue for the pharmaceutical industry in 2021 as new vaccines and treatments enter the market. Across the broader industry, oncology drugs continue to be a major growth driver, the industry’s late-stage...

Having received emergency use authorization from the FDA for their COVID-19 vaccine, Pfizer and BioNTech reached a significant milestone in an unprecedented effort to develop a safe and effective vaccine under accelerated timelines. What was their...